CKD Venture Capital
Profile and portfolio
CKD Venture Capital is the corporate venture arm of Chong Kun Dang, a pharmaceutical and biotech company. It was founded in 1997 and is based in Seoul, South Korea. It invests from seed to Series A. Sectors it names: biotech and life sciences, healthcare and digital health, artificial intelligence.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series A |
| Sectors | Biotech and life sciences, Healthcare and digital health, Artificial intelligence |
| Geography | Asia |
| Offices | Seoul, South Korea |
Sources: S2 Dailymedi: CKD Venture Capital invests in antibody, cancer vaccine and raw material companies; S1 CKD Venture Capital: home page.
Where it invests
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Chong Kun Dang | Single source | S1 |
| Parent industry | Pharmaceuticals and biotech | Single source | S1 |
| Founded | 1997 | Single source | S1 |
| Headquarters | Seoul, South Korea | Single source | S1 |
| Status | Active | Single source | S1 |
| Capital source | Parent and outside investors | Single source | S4 |
| Stages | Seed, Series A (inferred from announced rounds) | Estimate | S2 |
Fund vehicles
Portfolio
Public sources name 4 portfolio companies.S3
Every company on the CKD Venture Capital list
4 companies, as named in the sources cited.S3 Read the firm's list.
- Altogen
- Aston Science
- Fin Therapeutics
- Immunapps
Official pages
Read the firm's own pages for current information.
- Website ckdvc.co.kr/
Sources
- S1CKD Venture Capital: home pageFirm
- S2Dailymedi: CKD Venture Capital invests in antibody, cancer vaccine and raw material companiesPress
- S3Dailymedi: CKD Venture Capital invests in targeted protein degradation developer Fin TherapeuticsPress
- S4HitNews: pharma industry prepares seed investment in bio ventures (2023-03-13)Press
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by CKD Venture Capital or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.